 Antineoplastic Agents, Immunological
"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000074322
|
| MeSH Number(s) |
D27.505.954.248.384
|
| Concept/Terms |
Antineoplastics, Monoclonal Antibodies- Antineoplastics, Monoclonal Antibodies
- Antibodies Antineoplastics, Monoclonal
- Monoclonal Antibodies Antineoplastics
- Monoclonal Antibodies, Antineoplastic
- Antineoplastic Monoclonal Antibodies
- Antineoplastic MAbs
- Antineoplastics, Monoclonal Antibody
- Monoclonal Antibody Antineoplastics
- MAbs, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".
This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 | | 2017 | 8 | 3 | 11 | | 2018 | 16 | 10 | 26 | | 2019 | 11 | 6 | 17 | | 2020 | 5 | 6 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.
-
Akturk HK, Michels AW. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2020 08; 27(4):187-193.
-
Krane NA, Beswick DM, Sauer D, Detwiller K, Shindo M. Allergic Fungal Sinusitis Imitating an Aggressive Skull Base Lesion in the Setting of Pembrolizumab Immunotherapy. Ann Otol Rhinol Laryngol. 2021 Jan; 130(1):108-111.
-
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 06 04; 382(23):2207-2219.
-
Kapadia RK, Ney DE, Hannan M, Farley M, Pastula DM, Piquet AL. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab. J Neuroimmunol. 2020 07 15; 344:577259.
-
Kim MJ, Choi JR, Tae N, Wi TM, Kim KM, Kim DH, Lee ES. Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells. Int J Mol Sci. 2020 May 05; 21(9).
-
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 04 18; 395(10232):1278-1291.
-
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2021 01; 35(1):62-74.
-
Akturk HK, Michels AW. Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: An Underestimated Risk. Mayo Clin Proc. 2020 03; 95(3):614-615.
-
Libert D, Yuan CM, Masih KE, Galera P, Salem D, Shalabi H, Yates B, Delbrook C, Shern JF, Fry TJ, Khan J, Stetler-Stevenson M, Shah NN. Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. Leukemia. 2020 11; 34(11):3064-3069.
-
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol. 2020 04 01; 38(10):1041-1049.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|